Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects.

Trial Profile

Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2012

At a glance

  • Drugs LY 2886721 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jul 2012 Results presented at the 2012 International Conference on Alzheimer's Disease.
    • 25 Nov 2010 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top